Amendment of regulation 164 (effect of determination)U.K.
This section has no associated Explanatory Memorandum
134. In regulation 164(2)(a) and (b)—
(a)insert “ UK ” before “marketing authorisation”; and
[F1(b)for “Article 126a authorisation” insert “, only in relation to a product for sale or supply in Northern Ireland, an Article 126a authorisation or an EU marketing authorisation,”.]
Textual Amendments
F1Reg. 134(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 101
Commencement Information
I1Reg. 134 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1